The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Fri., May. 24, 7:09 AM

Slide #7. Auris Medical Holding Ltd. (NASDAQ:EARS) 1 for 20 Reverse Split

Announced: 4/30/2019
Stock Split: 1 for 20
Record Date: 4/30/2019
Pay Date: 5/1/2019
EARS Optionable?: No

Auris Medical Holding is a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. Co.'s most advanced product candidate, AM-101, is in Phase 3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the FDA. In two recently completed Phase 2 clinical trials, AM-101 demonstrated a favorable safety profile and statistically significant improvement in tinnitus loudness and other patient reported outcomes. Co. is also developing AM-111 for acute inner ear hearing loss.
EARS Detailed Information Page & Split History »

Company Name: 
Auris Medical Holding Ltd
Drugs & Pharmaceuticals

Open the EARS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Stock Splits Page |

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.